153 related articles for article (PubMed ID: 14652227)
21. Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis.
Bardia A; Novotny P; Sloan J; Barton D; Loprinzi C
Menopause; 2009; 16(3):477-83. PubMed ID: 19188850
[TBL] [Abstract][Full Text] [Related]
22. Update on CYP2D6 and its impact on tamoxifen therapy.
Goetz MP
Clin Adv Hematol Oncol; 2010 Aug; 8(8):536-8. PubMed ID: 20966889
[No Abstract] [Full Text] [Related]
23. Personalized tamoxifen: what is the best way forward?
Rae JM
J Clin Oncol; 2011 Aug; 29(24):3206-8. PubMed ID: 21768456
[No Abstract] [Full Text] [Related]
24. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
Van Poznak CH; Hayes DF
J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
[No Abstract] [Full Text] [Related]
25. Menopausal symptoms following tamoxifen treatment for breast cancer.
Barton DL
Oncology (Williston Park); 2008 Apr; 22(4 Suppl Nurse Ed):46-8. PubMed ID: 19856564
[TBL] [Abstract][Full Text] [Related]
26. Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.
Decaudin D; Etienne MC; De Cremoux P; Maciorowski Z; Vantelon JM; Voog E; Urien S; Tran-Perennou C; Renée N; Vielh P; Némati F; Pouillart P
J Natl Cancer Inst; 2004 Apr; 96(8):636-7. PubMed ID: 15100346
[No Abstract] [Full Text] [Related]
27. [CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients].
Barrière J; Formento JL; Milano G; Ferrero JM
Bull Cancer; 2010 Mar; 97(3):311-20. PubMed ID: 20123649
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen, hot flashes and recurrence in breast cancer.
Mortimer JE; Flatt SW; Parker BA; Gold EB; Wasserman L; Natarajan L; Pierce JP;
Breast Cancer Res Treat; 2008 Apr; 108(3):421-6. PubMed ID: 17541741
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.
Neven P; Jongen L; Lintermans A; Van Asten K; Blomme C; Lambrechts D; Poppe A; Wildiers H; Dieudonné AS; Brouckaert O; Decloedt J; Berteloot P; Verhoeven D; Joerger M; Vuylsteke P; Wynendaele W; Casteels M; Van Huffel S; Lybaert W; Van Ginderachter J; Paridaens R; Vergote I; Dezentjé VO; Van Calster B; Guchelaar HJ
Clin Cancer Res; 2018 May; 24(10):2312-2318. PubMed ID: 29459457
[No Abstract] [Full Text] [Related]
30. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO; Gelderblom H; Van Schaik RH; Vletter-Bogaartz JM; Van der Straaten T; Wessels JA; Kranenbarg EM; Berns EM; Seynaeve C; Putter H; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2014 Jan; 143(1):171-9. PubMed ID: 24265036
[TBL] [Abstract][Full Text] [Related]
31. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
32. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6 and tamoxifen: awaiting the denouement.
Brauch HB; Schroth W; Ingle JN; Goetz MP
J Clin Oncol; 2011 Dec; 29(34):4589-90; author reply 4590-1. PubMed ID: 22042960
[No Abstract] [Full Text] [Related]
34. Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.
Higgins MJ; Stearns V
Clin Chem; 2009 Aug; 55(8):1453-5. PubMed ID: 19541862
[No Abstract] [Full Text] [Related]
35. 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides.
Fan PW; Zhang F; Bolton JL
Chem Res Toxicol; 2000 Jan; 13(1):45-52. PubMed ID: 10649966
[TBL] [Abstract][Full Text] [Related]
36. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
[TBL] [Abstract][Full Text] [Related]
37. Endoxifen shows promise in breast cancer.
Cancer Discov; 2014 Feb; 4(2):OF1. PubMed ID: 24501306
[TBL] [Abstract][Full Text] [Related]
38. CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.
Jansen LE; Teft WA; Rose RV; Lizotte DJ; Kim RB
Breast Cancer Res Treat; 2018 Oct; 171(3):701-708. PubMed ID: 29980881
[TBL] [Abstract][Full Text] [Related]
39. Emphasizing the value of phenotyping in patients receiving tamoxifen.
Opdam FL; Dezentje VO; den Hartigh J; Guchelaar HJ; Gelderblom H
J Clin Oncol; 2012 Feb; 30(4):464; author reply 465. PubMed ID: 22184383
[No Abstract] [Full Text] [Related]
40. Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?
Lee CI; Fox P; Balakrishnar B; Balleine RL; Gao B; Provan P; Coulter S; Liddle C; Hui R; Wong M; Gurney H; Wilcken N
Breast; 2019 Aug; 46():52-57. PubMed ID: 31082762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
